Please login to Zacks.com or register to post a comment.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| SCIENTIFIC L | SCIL | 8.00% |
| NATUS MEDICA | BABY | 6.11% |
| SUMMER INFAN | SUMR | 6.02% |
| RADIANT LOGI | RLGT | 5.32% |
| NEW ORIENTAL | EDU | 4.51% |
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Full Analysis
Calgon Carbon Corporation provides services, products, and solutions for purifying water and air in the United States and internationally. The company is the world's largest manufacturer of granular activated carbon with production and operations in North America, Europe, and Asia. It has 16 operating centers and 23 sales and service centers around the world. Calgon Carbon was founded in 1942 and is based in Pittsburgh, Pennsylvania.
On Jan 14, Colgan Carbon announced that it had won a $1.5 million contract from Huntsman Textile Effects Co. Ltd. to supply wastewater treatment equipment and services at a facility in China. The company said it will supply activated carbon adsorption equipment and will provide reactivation services at Huntsman's manufacturing facility in Qingdao, China.
On Nov 2, Colgan reported a strong quarter that enabled the company to move back into profitable territory compared to the same quarter last year. Revenue rose 6.5% to $84.9 million. Net income took an impressive step forward, jumping to $4.9 million compared to a loss of $458,000 last year. This produced earnings of 10 cents per share, well ahead of analyst expectations of just six cents. Higher prices for activated carbon products and services and increased sales volumes from the industrial process and environmental air treatment markets helped boost results.
This marks the fourth time in four quarters that the company has surprised and beaten estimates, having done so by an average of four cents. Over this period the average estimate was 2 1/4 cents compared to average actual earnings of 6 cents.
Estimates for the company have been somewhat flat, but this Zacks Rank #1 Stock, operating in a Zacks Industry Rank #49 out of 218, is projected to post a very nice increase in its next-year earnings. The current-year estimate stands at 30 cents, with the next-year estimate significantly higher at 41 cents. The company's 2009 estimate stands at 53 cents and its 2010 estimate is pegged at 83 cents, representing a very nice upward trend in projected earnings.
In accordance with the recent strong quarter and upward trend in actual earnings, the company's chart formation looks very attractive, which has held-up remarkable well in this weak market. Shares are trading only marginally higher on the year, but again, this looks fairly attractive in light of the major indices logging sharp losses. Keep an eye on the short-term trend line that is applying upward pressure, and the 52-week high, just above $17. This stock looks like it can provide an opportunity for growth and returns while also representing a certain level of stability when other players are getting whipped around.
Read the full reports :
Analyst Report on CCC